신경아세포종 치료제 시장 : 유형별, 투여 경로별, 유통 채널별 - 세계 기회 분석과 산업 예측(2023-2032년)

Neuroblastoma Drugs Market By Type (Chemotherapy, Immunotherapy, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Online, Offline): Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 7,980,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,370,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

신경아세포종 치료제 시장은 2022년에는 7억 달러로 평가되며, 2023-2032년의 CAGR은 6.2%를 보이며, 2032년에는 13억 달러에 달할 것으로 추정되고 있습니다.

신경아세포종은 주로 유아에게 발생하는 암의 일종으로 보통 신장 상부의 부신에 발생하며, 5세 미만의 소아에서 가장 많이 진단되는 질환으로 대부분의 경우 영아에게 나타납니다. 이 암은 신경아세포라고 불리는 미성숙한 신경세포에서 발생하며, 신경아세포는 투쟁-도피 반응을 담당하는 교감신경계의 일부입니다.

신경모세포종은 자연적으로 퇴행하거나 성숙하는 것부터 공격적이고 빠르게 성장하는 것까지 그 행동이 매우 다양합니다. 신경아세포종의 증상은 종양의 위치와 크기에 따라 다르지만 복부 부종, 체중 감소, 과민성, 피로, 장 습관 변화 등이 있습니다. 신경아세포종 치료제는 암세포를 직접 공격하거나 종양 발생에 관여하는 생물학적 경로를 조절하여 암화된 신경아세포종 세포를 표적으로 삼아 증식을 억제하도록 고안되었습니다. 신경아세포종 치료는 수술, 화학요법, 방사선 요법, 면역요법 및 기타 표적치료제와 결합되는 경우가 많습니다.

신경아세포종 치료제 시장은 신경아세포종 발생률 증가, 연구개발 활동의 발전, 신경아세포종에 대한 인식 증가에 의해 주도되고 있습니다. 특히 소아 인구에서 신경아세포종 발생률과 유병률 증가는 신경아세포종 치료제 시장의 성장을 가속하는 매우 중요한 요인입니다. 예를 들어 2023년 미국 생물공학정보센터(NCBI)에 따르면 미국내 신경아세포종의 연간 발생률은 약 650건, 즉 소아 인구 100만 명당 10.2명이었습니다. 따라서 신경모세포종의 유병률 증가는 시장 성장에 기여할 효과적인 표적화된 약물 치료의 긴급한 필요성으로 이어졌습니다.

그 결과, 제약회사와 연구기관들은 이러한 건강 문제를 해결하기 위해 의약품 개발, 임상시험 및 공동 연구 구상에 대한 노력을 강화할 수밖에 없는 상황입니다. 질병 부담 증가에 대한 시장의 반응은 신경아세포종 환자의 예후와 삶의 질을 개선하기 위해 혁신적인 치료법을 발전시키는 것이 중요하다는 점을 강조하고 있습니다. 또한 제약업계는 종양학 연구와 의약품 개발에 많은 투자를 하고 있으며, 이는 시장 성장을 가속하고 있습니다. 신경모세포종은 소아 종양학의 하위 분야로서 이러한 광범위한 추세의 혜택을 받고 있으며, 새로운 약물의 발견과 개발에 할당되는 자금과 자원이 증가하고 있습니다. 예를 들어 미국 국립암연구소(NCI)는 신경아세포종 치료제인 지누툭시맙의 개발로 이어진 기초 연구에 많은 투자를 했습니다.

그러나 신경아세포종 치료의 높은 비용과 신경아세포종 치료제와 관련된 유해한 부작용은 신경아세포종 치료제 시장의 성장을 저해하는 요인으로 작용하고 있습니다. 반면, 신경아세포종 파이프라인 의약품물 증가는 시장 성장에 유리한 기회를 제공합니다. 또한 기존 화학요법 약물, 표적 약물 및 면역 요법 약물과 같은 다른 유형의 약물을 포함하는 병용 요법의 탐색은 치료 효과를 향상시킬 수있는 기회를 제공합니다.

이해관계자 주요 이점

• 이 보고서는 2022-2032년 신경아세포종 치료제 시장 분석 시장 부문, 현재 동향, 추정 및 역학에 대한 정량적 분석을 제공하여 우세한 신경아세포종 치료제 시장 기회를 식별합니다.
• 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• Porter's Five Forces 분석은 이해 관계자가 이익 중심의 비즈니스 결정을 내리고 공급자와 구매자의 네트워크를 강화할 수 있도록 구매자와 공급자의 잠재력을 밝힙니다.
• 신경아세포종 치료제 시장의 세분화에 대한 상세한 분석은 시장 기회를 결정하는 데 도움이 될 것입니다.
• 각 지역의 주요 국가는 세계 시장에 대한 매출 기여도에 따라 매핑되어 있습니다.
• 시장 기업의 포지셔닝은 벤치마킹을 용이하게 하고 시장 기업의 현재 위치를 명확하게 이해할 수 있습니다.
• 이 보고서에는 지역별 및 세계 신경아세포종 치료제 시장 동향, 주요 기업, 시장 부문, 용도, 시장 성장 전략에 대한 분석이 포함되어 있습니다.

이 보고서는 사용자 정의가 가능합니다.

• 규제 가이드라인
• 고객의 관심사에 따른 기업 개요 추가
• 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
• 기업 개요 확장 리스트
• 과거 시장 데이터
• 주요 기업의 세부 정보(위치, 연락처, 공급업체/벤더 네트워크 등 포함, 엑셀 형식)

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장의 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 촉진요인
    • 신경아종의 유병률 상승
    • 신경아종에 대한 정부의 인식 및 구상의 증가
    • 연구개발 활동의 증가
  • 억제요인
    • 부작용과 안전성에 대한 우려
  • 기회
    • 신흥 시장에서의 성장 기회
    • 파이프라인 제품의 증가

제4장 신경아세포종 치료제 시장 : 유형별

• 개요
• 화학요법
• 면역치료
• 기타

제5장 신경아세포종 치료제 시장 : 투여 경로별

• 개요
• 경구제
• 주사제

제6장 신경아세포종 치료제 시장 : 유통 채널별

• 개요
• 온라인
• 오프라인

제7장 신경아세포종 치료제 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타
• 라틴아메리카·중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • 남아프리카공화국
  • 기타

제8장 경쟁 상황

• 서론
• 주요 성공 전략
• 주요 10사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제9장 기업 개요

• Recordati Group
• AstraZeneca plc
• Bristol-Myers Squibb Company
• Cellectar Biosciences, Inc.
• Eli Lilly and Company
• MacroGenics Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• United Therapeutics Corporation
• Y-mabs Therapeutics, Inc.

KSA

영문 목차

영문목차

The neuroblastoma drugs market was valued for $0.7 billion in 2022 and is estimated to reach $1.3 billion by 2032, exhibiting a CAGR of 6.2% from 2023 to 2032. Neuroblastoma is a type of cancer that primarily affects young children, typically arising in the adrenal glands, which are located on top of the kidneys. It is the most diagnosed disease in children under five, with most cases appearing in infants. This cancer originates from immature nerve cells, called neuroblasts, which are part of the sympathetic nervous system responsible for the "fight or flight" response.

Neuroblastoma varies widely in its behavior, ranging from spontaneous regression or maturation to aggressive, rapidly spreading forms. Symptoms of neuroblastoma can vary based on the location and size of the tumor but may include abdominal swelling, weight loss, irritability, fatigue, and changes in bowel habits. Neuroblastoma drugs are designed to target and inhibit the growth of cancerous neuroblastoma cells, either by directly attacking the cancer cells or by modulating the biological pathways involved in tumor development. The treatment approach for neuroblastoma often involves a combination of surgery, chemotherapy, radiation therapy, immunotherapy, and other targeted therapies.

The neuroblastoma drugs market is driven by a rise in incidences of neuroblastoma, advancements in R&D activities, and growth in awareness of neuroblastoma. The increasing incidences and prevalence of neuroblastoma, particularly among pediatric populations, is a pivotal factor driving the growth of the neuroblastoma drugs market. For instance, according to the National Center for Biotechnology and Information (NCBI) in 2023, the annual incidence of neuroblastoma in the U.S. was approximately 650 cases, i.e., 10.2 per million children. Thus, the growing prevalence of neuroblastoma led to an urgent need for effective and targeted drug therapies which contribute toward the market growth.

Consequently, pharmaceutical companies and research institutions are compelled to intensify their efforts in drug development, clinical trials, and collaborative research initiatives to address this rising health concern. The market's response to the increasing disease burden emphasizes the importance of advancing innovative treatments to improve outcomes and quality of life for individuals affected by neuroblastoma. In addition, the pharmaceutical industry has been witnessing significant investments in oncology research and drug development, thereby boosting the market growth. Neuroblastoma, as a subset of pediatric oncology, benefits from this broader trend, with increased funding and resources allocated to discovering and developing novel drugs. For instance, the National Cancer Institute (NCI) has made substantial investments in basic research, leading to the development of dinutuximab, a treatment for neuroblastoma.

However, the high cost of neuroblastoma treatment, and harmful side effects associated with neuroblastoma drugs are the factors responsible for the impeding the growth of the neuroblastoma drug market. In contrast, rise in number of pipeline drugs for neuroblastoma provides lucrative opportunity to the market growth. In addition, the exploration of combination therapies involving different classes of drugs, such as traditional chemotherapeutics, targeted agents, and immunotherapies, offers opportunities for enhanced treatment efficacy.

The neuroblastoma drugs market is segmented into type, route of administration, distribution channel, and region. By type, the market is classified into chemotherapy, immunotherapy, and others. By route of administration, the market is segregated into oral and injectable. By distribution channel, the market is classified into online and offline. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). Major key players that operate in the neuroblastoma drugs market are Recordati Group,, AstraZeneca plc, Bristol-Myers Squibb Company, Cellectar Biosciences, Inc., Eli Lilly and Company, MacroGenics Inc, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, and Y-mabs Therapeutics, Inc. Key players operating in the market have adopted agreement, acquisition, partnership, and product approval as their key strategies to expand their product portfolio.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the neuroblastoma drugs market analysis from 2022 to 2032 to identify the prevailing neuroblastoma drugs market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the neuroblastoma drugs market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global neuroblastoma drugs market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

• Chemotherapy
• Immunotherapy
• Others

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Online
• Offline

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• AstraZeneca plc
• Bristol-Myers Squibb Company
• Cellectar Biosciences, Inc.
• Eli Lilly and Company
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• United Therapeutics Corporation
• Y-mabs Therapeutics, Inc.
• Recordati Group
• MacroGenics Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Moderate bargaining power of suppliers
  • 3.3.2. Moderate threat of new entrants
  • 3.3.3. Moderate threat of substitutes
  • 3.3.4. Moderate intensity of rivalry
  • 3.3.5. Moderate bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Rise in prevalence of neuroblastoma
    • 3.4.1.2. Growth in awareness & initiatives taken by the government for neuroblastoma
    • 3.4.1.3. Rise in R&D activities
  • 3.4.2. Restraints
    • 3.4.2.1. Adverse effects and safety concerns
  • 3.4.3. Opportunities
    • 3.4.3.1. Growth opportunities in emerging markets
    • 3.4.3.2. Rise in number of pipeline products

CHAPTER 4: NEUROBLASTOMA DRUGS MARKET, BY TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Chemotherapy
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Immunotherapy
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Others
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country

CHAPTER 5: NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Oral
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Injectable
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country

CHAPTER 6: NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Online
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Offline
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country

CHAPTER 7: NEUROBLASTOMA DRUGS MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Type
  • 7.2.3. Market size and forecast, by Route of Administration
  • 7.2.4. Market size and forecast, by Distribution Channel
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Type
    • 7.2.5.1.2. Market size and forecast, by Route of Administration
    • 7.2.5.1.3. Market size and forecast, by Distribution Channel
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Type
    • 7.2.5.2.2. Market size and forecast, by Route of Administration
    • 7.2.5.2.3. Market size and forecast, by Distribution Channel
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Type
    • 7.2.5.3.2. Market size and forecast, by Route of Administration
    • 7.2.5.3.3. Market size and forecast, by Distribution Channel
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Type
  • 7.3.3. Market size and forecast, by Route of Administration
  • 7.3.4. Market size and forecast, by Distribution Channel
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Type
    • 7.3.5.1.2. Market size and forecast, by Route of Administration
    • 7.3.5.1.3. Market size and forecast, by Distribution Channel
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Type
    • 7.3.5.2.2. Market size and forecast, by Route of Administration
    • 7.3.5.2.3. Market size and forecast, by Distribution Channel
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Type
    • 7.3.5.3.2. Market size and forecast, by Route of Administration
    • 7.3.5.3.3. Market size and forecast, by Distribution Channel
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Type
    • 7.3.5.4.2. Market size and forecast, by Route of Administration
    • 7.3.5.4.3. Market size and forecast, by Distribution Channel
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Type
    • 7.3.5.5.2. Market size and forecast, by Route of Administration
    • 7.3.5.5.3. Market size and forecast, by Distribution Channel
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Type
    • 7.3.5.6.2. Market size and forecast, by Route of Administration
    • 7.3.5.6.3. Market size and forecast, by Distribution Channel
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Type
  • 7.4.3. Market size and forecast, by Route of Administration
  • 7.4.4. Market size and forecast, by Distribution Channel
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Type
    • 7.4.5.1.2. Market size and forecast, by Route of Administration
    • 7.4.5.1.3. Market size and forecast, by Distribution Channel
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Type
    • 7.4.5.2.2. Market size and forecast, by Route of Administration
    • 7.4.5.2.3. Market size and forecast, by Distribution Channel
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Type
    • 7.4.5.3.2. Market size and forecast, by Route of Administration
    • 7.4.5.3.3. Market size and forecast, by Distribution Channel
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Type
    • 7.4.5.4.2. Market size and forecast, by Route of Administration
    • 7.4.5.4.3. Market size and forecast, by Distribution Channel
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Type
    • 7.4.5.5.2. Market size and forecast, by Route of Administration
    • 7.4.5.5.3. Market size and forecast, by Distribution Channel
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Type
    • 7.4.5.6.2. Market size and forecast, by Route of Administration
    • 7.4.5.6.3. Market size and forecast, by Distribution Channel
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Type
  • 7.5.3. Market size and forecast, by Route of Administration
  • 7.5.4. Market size and forecast, by Distribution Channel
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Type
    • 7.5.5.1.2. Market size and forecast, by Route of Administration
    • 7.5.5.1.3. Market size and forecast, by Distribution Channel
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Market size and forecast, by Type
    • 7.5.5.2.2. Market size and forecast, by Route of Administration
    • 7.5.5.2.3. Market size and forecast, by Distribution Channel
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Market size and forecast, by Type
    • 7.5.5.3.2. Market size and forecast, by Route of Administration
    • 7.5.5.3.3. Market size and forecast, by Distribution Channel
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Market size and forecast, by Type
    • 7.5.5.4.2. Market size and forecast, by Route of Administration
    • 7.5.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Recordati Group
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. AstraZeneca plc
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
• 9.3. Bristol-Myers Squibb Company
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
• 9.4. Cellectar Biosciences, Inc.
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
• 9.5. Eli Lilly and Company
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
• 9.6. MacroGenics Inc.
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
• 9.7. Pfizer Inc.
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
• 9.8. Teva Pharmaceutical Industries Ltd.
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
• 9.9. United Therapeutics Corporation
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
  • 9.9.7. Key strategic moves and developments
• 9.10. Y-mabs Therapeutics, Inc.
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments

관련자료